"","type","title","description","time_frame","population","measure","nct_id","group_id","non_inferiority_type","p_value","p_value_desc","method","arm","param_type","param_value","ci_percent","ci_n_sides","ci_lower_limit","ci_upper_limit","non_inferiority_desc"
"1","Primary","Total Use of Analgesics","The other primary endpoint of this study is the effectiveness of analgesia from the thoracotomy and chest tube site infiltrations as measured by the overall postsurgical analgesic use, (converted to morphine equivalents).","5 days","None of the patients completed to date 5: Lost to follow-up","Total Use of AnalgesicsThe other primary endpoint of this study is the effectiveness of analgesia from the thoracotomy and chest tube site infiltrations as measured by the overall postsurgical analgesic use, (converted to morphine equivalents).None of the patients completed to date 5: Lost to follow-upParticipantsMeasure","NCT02008370",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"2","Secondary","Patient Satisfaction","Overall rating of subject satisfaction with postsurgical pain control","10 days +/- 5 days","Lost of follow-up.","Patient SatisfactionOverall rating of subject satisfaction with postsurgical pain controlLost of follow-up.ParticipantsMeasure","NCT02008370",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"3","Secondary","Pain Scores","Subject reported surgical pain (using an 11-point numeric rating scale ).","First 5 post-op days","Lost to follow up","Pain ScoresSubject reported surgical pain (using an 11-point numeric rating scale ).Lost to follow upParticipantsMeasure","NCT02008370",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"4","Primary","Post Operative Pain Control","The primary objective is to evaluate analgesia following local infiltration of 30 mL Exparel or the same volume of 0.25% bupivacaine HCl with epinephrine or normal saline. The intensity of pain will be measured using a numerical rating scale (NRS-11) in which 0 represents no pain, and 10 represents extreme pain.","up to 4 days",NA,"Post Operative Pain ControlThe primary objective is to evaluate analgesia following local infiltration of 30 mL Exparel or the same volume of 0.25% bupivacaine HCl with epinephrine or normal saline. The intensity of pain will be measured using a numerical rating scale (NRS-11) in which 0 represents no pain, and 10 represents extreme pain.score on a scaleMeanFull RangeParticipantsMeasureHour 1Hour 2Day 1Day 2Day 3Day 4","NCT02104414",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"5","Secondary","Number of Oxycodone Tablets Taken","Number of postoperative opioid consumption - oxycodone tablets (5mg each)","up to 4 days",NA,"Number of Oxycodone Tablets TakenNumber of postoperative opioid consumption - oxycodone tablets (5mg each)tabletsMeanStandard DeviationParticipantsMeasureHour 1Hour 2Day 1Day 2Day 3Day 4","NCT02104414",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"6","Secondary","Postoperative Opioid Consumption - Hydromorphone I.V",NA,"1 hour and 2 hours post op",NA,"Postoperative Opioid Consumption - Hydromorphone I.VmgMeanStandard DeviationParticipantsMeasureHour 1Hour 2","NCT02104414",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"7","Secondary","Number of Participants With Postoperative Nausea and Vomiting","Number of participants with postoperative nausea and vomiting episodes","up to 4 days",NA,"Number of Participants With Postoperative Nausea and VomitingNumber of participants with postoperative nausea and vomiting episodesParticipantsCount of ParticipantsParticipantsMeasureHour 1Hour 2Day 1Day 2Day 3Day 4","NCT02104414",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"8","Secondary","Number of Participants With Pain During Bowel Movements","Number of participants with pain during postoperative bowel movements","Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days",NA,"Number of Participants With Pain During Bowel MovementsNumber of participants with pain during postoperative bowel movementsParticipantsCount of ParticipantsParticipantsMeasureDay 1Day 2Day 3Day 4","NCT02104414",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"9","Secondary","Number of Participants With Urinary Retention",NA,"up to 4 days",NA,"Number of Participants With Urinary RetentionParticipantsCount of ParticipantsParticipantsMeasureDay 1Day 2Day 3Day 4","NCT02104414",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"10","Primary","Cumulative Opioid Requirements for 72 Hours After Surgery","Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. The cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations will be recorded. Such assessment will be performed at the 3rd postoperative day (72 hours of operation).","Measured from end of surgery until 72 hours after the surgery",NA,"Cumulative Opioid Requirements for 72 Hours After SurgeryMeasured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. The cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations will be recorded. Such assessment will be performed at the 3rd postoperative day (72 hours of operation).mg morphine equivalents/dayMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"11","Primary","Cumulative Opioid Requirements at Postoperative Day 0","Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. The cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparation will be measured at postoperative day 0 (day of surgery).","From end of surgery until the end of postoperative day 0 (23:59pm of postoperative day 0)",NA,"Cumulative Opioid Requirements at Postoperative Day 0Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. The cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparation will be measured at postoperative day 0 (day of surgery).mg morphine equivalents/dayMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"12","Primary","Cumulative Opioid Requirements at Postoperative Day 1","Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations, measured at postoperative day 1","From 00:00am of postoperative day 1 until (23:59pm of postoperative day 1)",NA,"Cumulative Opioid Requirements at Postoperative Day 1Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations, measured at postoperative day 1mg morphine equivalents/dayMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"13","Primary","Cumulative Opioid Requirements at Postoperative Day 2","Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations, measured at postoperative day 2","From 00:00 of postoperative day 2 until 23:59pm of postoperative day 2",NA,"Cumulative Opioid Requirements at Postoperative Day 2Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations, measured at postoperative day 2mg morphine equivalents/dayMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"14","Primary","Cumulative Opioid Requirements at Postoperative Day 3","Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations, measured at postoperative day 3","From 00:00 of postoperative day 3 until 23:59pm of postoperative day 3",NA,"Cumulative Opioid Requirements at Postoperative Day 3Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose. Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations, measured at postoperative day 3mg morphine equivalents/dayMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"15","Secondary","Opioid Requirements for Total Length of Hospital Stay","Cumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations administered during the entire length of hospital stay. Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose.","Measured from end of surgery until the time of hospital discharge, up to a maximum of 6 days",NA,"Opioid Requirements for Total Length of Hospital StayCumulative dose of opioids administered intravenously (infused through a patient-controlled analgesia device as well as the quantity of opioids administered intravenously as rescue, if needed) and the quantity of opioids administered through oral preparations administered during the entire length of hospital stay. Measured in milligrams or micrograms as appropriate and converted to oral morphine equivalent daily dose.mg morphine equivalents/dayMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"16","Secondary","Pain Scores at Postoperative Day 0","Measured using a 100mm Visual Analog Scale, at the end of the first of postoperative day 0 (day of surgery).
The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.","Measured once, from end of surgery until the end of postoperative day 0 (23:59pm of the day of surgery)",NA,"Pain Scores at Postoperative Day 0Measured using a 100mm Visual Analog Scale, at the end of the first of postoperative day 0 (day of surgery).
The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.score on a scaleMedianInter-Quartile RangeParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"17","Secondary","Pain Scores at Postoperative Day 1","Measured using a 100mm Visual Analog Scale, at the end of the postoperative day 1.
The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.","Measured once, from 00:00am of postoperative day 1 until the end of postoperative day 1 (23:59pm of postoperative day 1)",NA,"Pain Scores at Postoperative Day 1Measured using a 100mm Visual Analog Scale, at the end of the postoperative day 1.
The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.score on a scaleMedianInter-Quartile RangeParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"18","Secondary","Pain Scores at Postoperative Day 2","Measured using a 100mm Visual Analog Scale, at the end of the postoperative day 2 The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.","Measured once, from 00:00am of postoperative day 2 until the end of postoperative day 2 (23:59pm of postoperative day 2)",NA,"Pain Scores at Postoperative Day 2Measured using a 100mm Visual Analog Scale, at the end of the postoperative day 2 The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.score on a scaleMedianInter-Quartile RangeParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"19","Secondary","Pain Scores at Postoperative Day 3","Measured using a 100mm Visual Analog Scale, at the end of the postoperative day 3 The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.","Measured once, from 00:00am of postoperative day 3 until the end of postoperative day 3 (23:59pm of postoperative day 3)",NA,"Pain Scores at Postoperative Day 3Measured using a 100mm Visual Analog Scale, at the end of the postoperative day 3 The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.score on a scaleMedianInter-Quartile RangeParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"20","Secondary","Length of Hospital Stay","Measured in days, being the difference from day of surgery until the day of hospital discharge.
The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.","From the day of surgery until the day of hospital discharge, up to a maximum of 30 days",NA,"Length of Hospital StayMeasured in days, being the difference from day of surgery until the day of hospital discharge.
The scale ranges from 0mm (No pain) to 100mm (Pain as bad as it could possibly be). A paper-based version of the VAS will be used, containing a 100mm line, where the left-end (0mm) contains the sentence ""No Pain"" and in the right-end (100mm) contains the sentence ""Pain as bad as it could possibly be"". Patients will be asked to indicate on the line where the pain is in relation to the two extremes. This will be performed with a pen. Measure with a ruler will be performed from the left hand side to the mark and this will be recorded in mm. Lower values represent less pain and higher values represent more pain. There are no subscale components for this measurement.DaysMedianInter-Quartile RangeParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"21","Secondary","30-day Pain Scores","Measured using the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Intensity 3a survey. This survey has 3 questions:(1) How intense was your pain as its worst? (2) How intense was your average pain? and (3) What is your level of pain right now?. Each question has 5 response options ranging in value from 1 to 5. To find the total raw score, sum of the values for each question is performed; lowest possible raw score is 3 and highest possible raw score is 15.A raw score of 10 converts to a T-score of 54.5 with a standard error (SE) of 2.9. Thus, the 95% confidence interval around the observed score ranges from 48.8 to 54.5 (T-score + (1.96*SE) or 54.5 + (1.96*2.9). A score of 50 is the average for the United States general population with a standard deviation of 10. For negatively-worded concepts like Pain Intensity, a T-score of 60 is one SD worse than average. By comparison, a Pain Intensity Tscore of 40 is one SD better than average.","Measured during the 30-day follow-up visit, expected to occur 30-days after the day of surgery, up to a maximum of 90 days",NA,"30-day Pain ScoresMeasured using the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Intensity 3a survey. This survey has 3 questions:(1) How intense was your pain as its worst? (2) How intense was your average pain? and (3) What is your level of pain right now?. Each question has 5 response options ranging in value from 1 to 5. To find the total raw score, sum of the values for each question is performed; lowest possible raw score is 3 and highest possible raw score is 15.A raw score of 10 converts to a T-score of 54.5 with a standard error (SE) of 2.9. Thus, the 95% confidence interval around the observed score ranges from 48.8 to 54.5 (T-score + (1.96*SE) or 54.5 + (1.96*2.9). A score of 50 is the average for the United States general population with a standard deviation of 10. For negatively-worded concepts like Pain Intensity, a T-score of 60 is one SD worse than average. By comparison, a Pain Intensity Tscore of 40 is one SD better than average.T-ScoreMedianInter-Quartile RangeParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"22","Secondary","30-day Patient-Reported Quality of Life","Measured using the Hernia Related Quality of Life survey (HerQLes) during the 30-day follow-up visit. The HerQLes is a valid and reliable hernia-specific quality of life measure. Each questions has 6 response options ranging in value from one to six. To find the raw score for the HerQles, a sum of the values of the response to each question is performed. For example, the lowest possible score is 12; the highest possible score is 72. All questions must be answered to provide a valid score. Mean and standard deviations of the scores of the entire study population will be calculated. Next, the Z score will be calculated as follows:
(Raw score-mean) / Standard Deviation. Next step is to calculate the Standard Score, as follows: (-(Z score)*Mean)+Standard Deviation. The standard score will be used for comparisons and reports, and should provide a value ranging from 0 to 100. Lower scores means lower quality of life and higher scores means higher quality of life.","Measured during the 30-day follow-up visit, expected to occur 30-days after the day of surgery, up to a maximum of 90 days",NA,"30-day Patient-Reported Quality of LifeMeasured using the Hernia Related Quality of Life survey (HerQLes) during the 30-day follow-up visit. The HerQLes is a valid and reliable hernia-specific quality of life measure. Each questions has 6 response options ranging in value from one to six. To find the raw score for the HerQles, a sum of the values of the response to each question is performed. For example, the lowest possible score is 12; the highest possible score is 72. All questions must be answered to provide a valid score. Mean and standard deviations of the scores of the entire study population will be calculated. Next, the Z score will be calculated as follows:
(Raw score-mean) / Standard Deviation. Next step is to calculate the Standard Score, as follows: (-(Z score)*Mean)+Standard Deviation. The standard score will be used for comparisons and reports, and should provide a value ranging from 0 to 100. Lower scores means lower quality of life and higher scores means higher quality of life.Z-ScoreMeanStandard DeviationParticipantsMeasure","NCT03541941",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"23","Primary","Opioid Use as Measured by Questionnaire","Compare time to first opioid use over 72 hours between groups","Daily through the third day (72 hours) post-surgery",NA,"Opioid Use as Measured by QuestionnaireCompare time to first opioid use over 72 hours between groupshoursNumberParticipantsMeasure","NCT02499575",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"24","Primary","Total Opioid Use as Measured by Questionnaire","Compare total opioid use (reported as total morphine equivalents) over 72 hours between groups.","Daily through the third day (72 hours) post-surgery",NA,"Total Opioid Use as Measured by QuestionnaireCompare total opioid use (reported as total morphine equivalents) over 72 hours between groups.morphine equivalentsNumberParticipantsMeasure","NCT02499575",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"25","Secondary","Pain Relief Measured by Defense and Veterans Pain Scale","Evaluate patient-reported pain scores (scale of 0 (no pain) - 10 (worst pain)) at 0, 6, 12, 24, 36, 48, 60, and 72 hours following surgery","Through 72 hours post-surgery (0, 6, 12, 24, 36, 48, 60, and 72 hours post-surgery)",NA,"Pain Relief Measured by Defense and Veterans Pain ScaleEvaluate patient-reported pain scores (scale of 0 (no pain) - 10 (worst pain)) at 0, 6, 12, 24, 36, 48, 60, and 72 hours following surgeryunits on scale of 0 -10NumberParticipantsMeasurePain score time 0Pain score time 6hrsPain score time 12hrsPain score time 24hrsPain score time 36hrsPain score time 48hrsPain score time 60hrsPain score time 72hrs","NCT02499575",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"26","Primary","Hospital Length of Stay","Inpatient post-operative stay after undergoing TKA procedure","Through entire inpatient hospital stay (lasted from 1 day to 1 week)",NA,"Hospital Length of StayInpatient post-operative stay after undergoing TKA procedureHoursMeanStandard DeviationParticipantsMeasure","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Exparel",NA,NA,NA,NA,NA,NA,NA
"27","Primary","Hospital Length of Stay","Inpatient post-operative stay after undergoing TKA procedure","Through entire inpatient hospital stay (lasted from 1 day to 1 week)",NA,"Hospital Length of StayInpatient post-operative stay after undergoing TKA procedureHoursMeanStandard DeviationParticipantsMeasure","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Control",NA,NA,NA,NA,NA,NA,NA
"28","Primary","Inpatient Opioid Use","Opioid usage during their inpatient post-operative hospital stay","1 week",NA,"Inpatient Opioid UseOpioid usage during their inpatient post-operative hospital stayMilimorphine Equivalents/DayMeanStandard DeviationParticipantsMeasure","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Exparel",NA,NA,NA,NA,NA,NA,NA
"29","Primary","Inpatient Opioid Use","Opioid usage during their inpatient post-operative hospital stay","1 week",NA,"Inpatient Opioid UseOpioid usage during their inpatient post-operative hospital stayMilimorphine Equivalents/DayMeanStandard DeviationParticipantsMeasure","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Control",NA,NA,NA,NA,NA,NA,NA
"30","Primary","Numeric Rating Scale (NRS) Pain Score Improvement","Measured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10). Change in NRS Pain Score from pre-operative levels. Positive changes indicate a decrease in pain levels from pre-operative levels.","6 weeks","Number of patients available in Post-operative day (POD) 2 lower secondary to earlier discharges. Number of patients available for analysis in in POD 7-42 time points secondary to their follow up). To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.","Numeric Rating Scale (NRS) Pain Score ImprovementMeasured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10). Change in NRS Pain Score from pre-operative levels. Positive changes indicate a decrease in pain levels from pre-operative levels.Number of patients available in Post-operative day (POD) 2 lower secondary to earlier discharges. Number of patients available for analysis in in POD 7-42 time points secondary to their follow up). To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.units on a scaleMeanStandard DeviationParticipantsMeasurePOD 0ParticipantsClassPOD 1ParticipantsClassPOD 2ParticipantsClassPOD 7ParticipantsClassPOD 14ParticipantsClassPOD 28ParticipantsClassPOD 42ParticipantsClass","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Exparel",NA,NA,NA,NA,NA,NA,NA
"31","Primary","Numeric Rating Scale (NRS) Pain Score Improvement","Measured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10). Change in NRS Pain Score from pre-operative levels. Positive changes indicate a decrease in pain levels from pre-operative levels.","6 weeks","Number of patients available in Post-operative day (POD) 2 lower secondary to earlier discharges. Number of patients available for analysis in in POD 7-42 time points secondary to their follow up). To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.","Numeric Rating Scale (NRS) Pain Score ImprovementMeasured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10). Change in NRS Pain Score from pre-operative levels. Positive changes indicate a decrease in pain levels from pre-operative levels.Number of patients available in Post-operative day (POD) 2 lower secondary to earlier discharges. Number of patients available for analysis in in POD 7-42 time points secondary to their follow up). To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.units on a scaleMeanStandard DeviationParticipantsMeasurePOD 0ParticipantsClassPOD 1ParticipantsClassPOD 2ParticipantsClassPOD 7ParticipantsClassPOD 14ParticipantsClassPOD 28ParticipantsClassPOD 42ParticipantsClass","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Control",NA,NA,NA,NA,NA,NA,NA
"32","Primary","Outpatient Opioid Use","Opioid usage in the immediate post-operative period after hospital discharge","6 weeks",NA,"Outpatient Opioid UseOpioid usage in the immediate post-operative period after hospital dischargeMilimorphine Equivalents/DayMeanStandard DeviationParticipantsMeasure","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Exparel",NA,NA,NA,NA,NA,NA,NA
"33","Primary","Outpatient Opioid Use","Opioid usage in the immediate post-operative period after hospital discharge","6 weeks",NA,"Outpatient Opioid UseOpioid usage in the immediate post-operative period after hospital dischargeMilimorphine Equivalents/DayMeanStandard DeviationParticipantsMeasure","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Control",NA,NA,NA,NA,NA,NA,NA
"34","Primary","WOMAC Score","Western Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68). Measured as change in score from baseline levels. Positive scores indicate an improvement in WOMAC scores from pre-operative levels.","6 weeks","Number of patients available for analysis in in POD 7-42 time points decreased secondary to their follow up. To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.","WOMAC ScoreWestern Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68). Measured as change in score from baseline levels. Positive scores indicate an improvement in WOMAC scores from pre-operative levels.Number of patients available for analysis in in POD 7-42 time points decreased secondary to their follow up. To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.units on a scaleMeanStandard DeviationParticipantsMeasurePOD 7 Pain SubscoreParticipantsClassPOD 7 Stiffness SubscoreParticipantsClassPOD 7 Physical Function SubscoreParticipantsClassPOD 7 Total ScoreParticipantsClassPOD 14 Pain SubscoreParticipantsClassPOD 14 Stiffness SubscoreParticipantsClassPOD 14 Physical Function SubscoreParticipantsClassPOD 14 Total ScoreParticipantsClassPOD 28 Pain SubscoreParticipantsClassPOD 28 Stiffness SubscoreParticipantsClassPOD 28 Physical Function SubscoreParticipantsClassPOD 28 Total ScoreParticipantsClassPOD 42 Pain SubscoreParticipantsClassPOD 42 Stiffness SubscoreParticipantsClassPOD 42 Physical Function SubscoreParticipantsClassPOD 42 Total ScoreParticipantsClass","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Exparel",NA,NA,NA,NA,NA,NA,NA
"35","Primary","WOMAC Score","Western Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68). Measured as change in score from baseline levels. Positive scores indicate an improvement in WOMAC scores from pre-operative levels.","6 weeks","Number of patients available for analysis in in POD 7-42 time points decreased secondary to their follow up. To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.","WOMAC ScoreWestern Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68). Measured as change in score from baseline levels. Positive scores indicate an improvement in WOMAC scores from pre-operative levels.Number of patients available for analysis in in POD 7-42 time points decreased secondary to their follow up. To account for this, both an ""intention to treat"" and a ""per protocol"" analysis were completed.units on a scaleMeanStandard DeviationParticipantsMeasurePOD 7 Pain SubscoreParticipantsClassPOD 7 Stiffness SubscoreParticipantsClassPOD 7 Physical Function SubscoreParticipantsClassPOD 7 Total ScoreParticipantsClassPOD 14 Pain SubscoreParticipantsClassPOD 14 Stiffness SubscoreParticipantsClassPOD 14 Physical Function SubscoreParticipantsClassPOD 14 Total ScoreParticipantsClassPOD 28 Pain SubscoreParticipantsClassPOD 28 Stiffness SubscoreParticipantsClassPOD 28 Physical Function SubscoreParticipantsClassPOD 28 Total ScoreParticipantsClassPOD 42 Pain SubscoreParticipantsClassPOD 42 Stiffness SubscoreParticipantsClassPOD 42 Physical Function SubscoreParticipantsClassPOD 42 Total ScoreParticipantsClass","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Wilcoxon (Mann-Whitney)","Control",NA,NA,NA,NA,NA,NA,NA
"36","Secondary","Number of Participants Needing to be Readmitted to the Hospital Secondary to Inadequate Pain Control Post-operatively","Rate of needing to be readmitted to the hospital secondary to inadequate pain control post-operatively at any point during the study period.","6 weeks",NA,"Number of Participants Needing to be Readmitted to the Hospital Secondary to Inadequate Pain Control Post-operativelyRate of needing to be readmitted to the hospital secondary to inadequate pain control post-operatively at any point during the study period.ParticipantsCount of ParticipantsParticipantsMeasure","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Fisher Exact","Exparel",NA,NA,NA,NA,NA,NA,NA
"37","Secondary","Number of Participants Needing to be Readmitted to the Hospital Secondary to Inadequate Pain Control Post-operatively","Rate of needing to be readmitted to the hospital secondary to inadequate pain control post-operatively at any point during the study period.","6 weeks",NA,"Number of Participants Needing to be Readmitted to the Hospital Secondary to Inadequate Pain Control Post-operativelyRate of needing to be readmitted to the hospital secondary to inadequate pain control post-operatively at any point during the study period.ParticipantsCount of ParticipantsParticipantsMeasure","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Fisher Exact","Control",NA,NA,NA,NA,NA,NA,NA
"38","Secondary","Number of Participants Needing to be Admitted to an Inpatient Rehabilitation Facility Post-Operatively","Rate of needing to be discharged to an inpatient rehabilitation facility after TKA procedure secondary to inadequate pain control and functional recovery","1 week",NA,"Number of Participants Needing to be Admitted to an Inpatient Rehabilitation Facility Post-OperativelyRate of needing to be discharged to an inpatient rehabilitation facility after TKA procedure secondary to inadequate pain control and functional recoveryParticipantsCount of ParticipantsParticipantsMeasure","NCT04910165","O1","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Fisher Exact","Exparel",NA,NA,NA,NA,NA,NA,NA
"39","Secondary","Number of Participants Needing to be Admitted to an Inpatient Rehabilitation Facility Post-Operatively","Rate of needing to be discharged to an inpatient rehabilitation facility after TKA procedure secondary to inadequate pain control and functional recovery","1 week",NA,"Number of Participants Needing to be Admitted to an Inpatient Rehabilitation Facility Post-OperativelyRate of needing to be discharged to an inpatient rehabilitation facility after TKA procedure secondary to inadequate pain control and functional recoveryParticipantsCount of ParticipantsParticipantsMeasure","NCT04910165","O2","Superiority","<0.05","p-values reported are calculated by the listed statistical test.","Fisher Exact","Control",NA,NA,NA,NA,NA,NA,NA
"40","Primary","Overall Amounts of Pain Medications Consumed Through Post-operative Day 7","Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets.","Assessed daily for 7 days post-procedure","4 participants from the Exparel group and 6 participants from the standard group did not return a questionnaire.","Overall Amounts of Pain Medications Consumed Through Post-operative Day 7Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets.4 participants from the Exparel group and 6 participants from the standard group did not return a questionnaire.tabletsNumberParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"41","Secondary","Scores on a Analog Pain Scale (7 Days)","Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.","Assessed at day 7 post-procedure",NA,"Scores on a Analog Pain Scale (7 Days)Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.Median score on postoperative day 7MedianInter-Quartile RangeParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"42","Secondary","Scores on an Analog Pain Scale (30 Days)","Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.","Assessed at 30 days post-procedure","42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.","Scores on an Analog Pain Scale (30 Days)Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.Median score on postoperative day 30MedianInter-Quartile RangeParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"43","Secondary","Number of Patients With Paresthesias (Postoperatively at 7 Days)","Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves since the procedure.","Assessed at day 7 post-procedure",NA,"Number of Patients With Paresthesias (Postoperatively at 7 Days)Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves since the procedure.ParticipantsCount of ParticipantsParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"44","Secondary","Proportion of Patients With Paresthesias (Postoperatively at 30 Days)","Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves","Assessed at day 30 post-procedure","42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.","Proportion of Patients With Paresthesias (Postoperatively at 30 Days)Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.ParticipantsCount of ParticipantsParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"45","Secondary","Hospital Length of Stay","Median length of stay in days until discharge.","From end of procedure until discharge, usually 0-2 days.",NA,"Hospital Length of StayMedian length of stay in days until discharge.daysMedianInter-Quartile RangeParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"46","Secondary","Return to Baseline Activity","Using surveys, patients are asked if they have been able to return to baseline activity levels.","Assessed at 30 days post-procedure","42 subjects in the Exparel group and 47 subjects in the standard group completed the 30 day survey.","Return to Baseline ActivityUsing surveys, patients are asked if they have been able to return to baseline activity levels.42 subjects in the Exparel group and 47 subjects in the standard group completed the 30 day survey.ParticipantsCount of ParticipantsParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"47","Secondary","Return to Work","Using surveys, patients are asked if they have been able to return to work.","Assessed at 30 days post-procedure","42 subjects in the Exparel group and 47 patients in the standard group completed the 30-day survey.","Return to WorkUsing surveys, patients are asked if they have been able to return to work.42 subjects in the Exparel group and 47 patients in the standard group completed the 30-day survey.ParticipantsCount of ParticipantsParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"48","Secondary","Days Until Return to Work","Using surveys, the number of days to return to work was assessed for patients who were able to return to work.","Assessed at 30 days post-procedure","At the 30-day call, 24 subjects in the Exparel group and 17 subjects in the standard group indicated that they were able to return to work. Number of days were assessed for these subjects.","Days Until Return to WorkUsing surveys, the number of days to return to work was assessed for patients who were able to return to work.At the 30-day call, 24 subjects in the Exparel group and 17 subjects in the standard group indicated that they were able to return to work. Number of days were assessed for these subjects.daysMedianInter-Quartile RangeParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"49","Secondary","Overall Hospital Cost","Overall hospital cost of patient procedure and stay will be assessed.","Total cost assessed from patient registration until discharge to home (usually 0-2 days).","Data on hospital cost was not collected.","Overall Hospital CostOverall hospital cost of patient procedure and stay will be assessed.Data on hospital cost was not collected.ParticipantsMeasure","NCT02499159",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"50","Primary","Post-operative Pain","Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain","4hrs after surgery",NA,"Post-operative PainPrimary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most painscore on a scaleMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"51","Primary","Post-operative Pain","Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain","8hrs after surgery",NA,"Post-operative PainPrimary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most painscore on a scaleMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"52","Primary","Post-operative Pain","Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain","12hrs after surgery",NA,"Post-operative PainPrimary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most painscore on a scaleMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"53","Primary","Post-operative Pain","Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain","24hrs after surgery",NA,"Post-operative PainPrimary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most painscore on a scaleMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"54","Primary","Post-operative Pain","Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain","48hrs after surgery",NA,"Post-operative PainPrimary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most painscore on a scaleMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"55","Secondary","Time to Ambulation","Measure of time to ambulation with physical therapy","24 and 48 hours after surgery",NA,"Time to AmbulationMeasure of time to ambulation with physical therapyDaysMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"56","Secondary","Postoperative Total Morphine Equivalent","Total dose in milligrams of opiates measured in total morphine equivalents. This was measured by calculating the sum of total morphine equivalents administered within 48 hours postoperatively. Assessed at 12, 24, 36, 48 hours after surgery, total postoperative total morphine equivalents at 48 hours after surgery reported","48 hours after surgery",NA,"Postoperative Total Morphine EquivalentTotal dose in milligrams of opiates measured in total morphine equivalents. This was measured by calculating the sum of total morphine equivalents administered within 48 hours postoperatively. Assessed at 12, 24, 36, 48 hours after surgery, total postoperative total morphine equivalents at 48 hours after surgery reportedMorphine EquivalentMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"57","Secondary","Delirium Scale Measurements","Assessment of post-operative delirium based on Short Confusion Assessment Method","24 and 48 hours after surgery",NA,"Delirium Scale MeasurementsAssessment of post-operative delirium based on Short Confusion Assessment MethodParticipantsCount of ParticipantsParticipantsMeasureAt 24 HoursAt 48 HoursNo Delirium","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"58","Secondary","Length of Stay","Total days until discharge from hospital","7 days from day of admission",NA,"Length of StayTotal days until discharge from hospitalDaysMeanStandard DeviationParticipantsMeasure","NCT03502018",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"59","Primary","Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section","The primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean SectionThe primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED, mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O1","Superiority","0.0117",NA,"ANCOVA","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","LSM treatment difference","-16.5","95","2-Sided","-30.8","-2.2",NA
"60","Primary","Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean Section","The primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 72 Hours After TAP Infiltration During Elective Cesarean SectionThe primary endpoint is the total postsurgical opioid consumption (mg) in oral morphine equivalent dose (OMED) through 72 hours.Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED, mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O2","Superiority","0.0117",NA,"ANCOVA","IR Bupivacaine","LSM treatment difference","-16.5","95","2-Sided","-30.8","-2.2",NA
"61","Secondary","Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours","AUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= ""no pain"" to 30 cm=""pain as bad as it could be"").
Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, ""How much pain are you experiencing right now?"" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment.
Note higher AUC means more pain over time.","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 HoursAUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= ""no pain"" to 30 cm=""pain as bad as it could be"").
Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, ""How much pain are you experiencing right now?"" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment.
Note higher AUC means more pain over time.Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)cm*hrLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O1","Non-Inferiority","0.0020",NA,"ANCOVA","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","LSM treatment difference (SE)","-30.6","95","2-Sided","-75.9","14.7","Pre-specified non-inferiority margin of 36"
"62","Secondary","Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 Hours","AUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= ""no pain"" to 30 cm=""pain as bad as it could be"").
Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, ""How much pain are you experiencing right now?"" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment.
Note higher AUC means more pain over time.","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Area Under the Curve (AUC) for Visual Analog Scale (VAS) Pain Scores Through 72 HoursAUC for VAS pain scores through 72 hours. Pain intensity scores were measured on a 10-cm VAS (0 cm= ""no pain"" to 30 cm=""pain as bad as it could be"").
Subjects were evaluated for pain intensity scores at rest using the 10-cm VAS at rest at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery and then once daily (at noon ± 4 hours) through Day 14. To assess pain intensity (VAS) at rest, the subject should rest quietly in a supine or seated position that does not exacerbate her postsurgical pain for 3-5 minutes before entering the pain score. While in the hospital, subjects are to assess, ""How much pain are you experiencing right now?"" and a vertical mark is placed on a 10-cm straight line to indicate the level of pain experienced at the time of assessment.
Note higher AUC means more pain over time.Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)cm*hrLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O2","Non-Inferiority","0.0020",NA,"ANCOVA","IR Bupivacaine","LSM treatment difference (SE)","-30.6","95","2-Sided","-75.9","14.7","Pre-specified non-inferiority margin of 36"
"63","Secondary","Opioid Spared Subjects Through 72 Hours","Subjects were considered opioid-spared if:
For 0-72 hours opioid consumption, all doses add up to ≤15mg (oral morphine equivalent dose [OMED])
AND the overall benefit of anesthesia score (OBAS) score was 0 for questions 2, 3, 4, 5, and 6. For the OBAS questionnaire, 0 is considered minimal pain and 4 is considered maximum imaginable pain.","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Opioid Spared Subjects Through 72 HoursSubjects were considered opioid-spared if:
For 0-72 hours opioid consumption, all doses add up to ≤15mg (oral morphine equivalent dose [OMED])
AND the overall benefit of anesthesia score (OBAS) score was 0 for questions 2, 3, 4, 5, and 6. For the OBAS questionnaire, 0 is considered minimal pain and 4 is considered maximum imaginable pain.Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)percent of participantsNumberParticipantsMeasure","NCT03176459","O1","Superiority","0.0012",NA,"LSM probability from logistic regression","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","Odds Ratio (OR)","3.51","95","2-Sided","1.557","7.906",NA
"64","Secondary","Total Postsurgical Opioid Consumption Through 24 Hours",NA,"0-24 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 24 HoursEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O1","Superiority",".0543",NA,"ANCOVA","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","Least squares treatment difference","-3.2",NA,"2-Sided",NA,NA,NA
"65","Secondary","Total Postsurgical Opioid Consumption Through 24 Hours",NA,"0-24 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 24 HoursEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O2","Superiority",".0543",NA,"ANCOVA","IR Bupivacaine","Least squares treatment difference","-3.2",NA,"2-Sided",NA,NA,NA
"66","Secondary","Total Postsurgical Opioid Consumption Through 48 Hours",NA,"0-48 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 48 HoursEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O1","Superiority",".0096",NA,"ANCOVA","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","Least squares treatment difference","-11.4",NA,"1-Sided",NA,NA,NA
"67","Secondary","Total Postsurgical Opioid Consumption Through 48 Hours",NA,"0-48 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 48 HoursEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O2","Superiority",".0096",NA,"ANCOVA","IR Bupivacaine","Least squares treatment difference","-11.4",NA,"1-Sided",NA,NA,NA
"68","Secondary","Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)",NA,"0-168 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O1","Superiority",".0175",NA,"ANCOVA","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","Least squares treatment difference","-22.4",NA,"2-Sided",NA,NA,NA
"69","Secondary","Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)",NA,"0-168 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 168 Hours (Day 7)Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O2","Superiority",".0175",NA,"ANCOVA","IR Bupivacaine","Least squares treatment difference","-22.4",NA,"2-Sided",NA,NA,NA
"70","Secondary","Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)",NA,"0-336 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O1","Superiority",".0542",NA,"ANCOVA","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","Least squares treatment difference","-19.6",NA,"2-Sided",NA,NA,NA
"71","Secondary","Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)",NA,"0-336 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Total Postsurgical Opioid Consumption Through 336 Hours (Day 14)Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)MED mgLeast Squares MeanStandard ErrorParticipantsMeasure","NCT03176459","O2","Superiority",".0542",NA,"ANCOVA","IR Bupivacaine","Least squares treatment difference","-19.6",NA,"2-Sided",NA,NA,NA
"72","Secondary","Time to First Rescue Medication Use","The time to a subject's first use of an opioid medication for breakthrough pain after the end of surgery","From the end of surgery","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Time to First Rescue Medication UseThe time to a subject's first use of an opioid medication for breakthrough pain after the end of surgeryEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)hoursMedianFull RangeParticipantsMeasure","NCT03176459","O1","Superiority","0.7536",NA,"Regression, Cox","EXPAREL 266mg + Immediate Release (IR) Bupivacaine",NA,NA,NA,NA,NA,NA,NA
"73","Secondary","Time to First Rescue Medication Use","The time to a subject's first use of an opioid medication for breakthrough pain after the end of surgery","From the end of surgery","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Time to First Rescue Medication UseThe time to a subject's first use of an opioid medication for breakthrough pain after the end of surgeryEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)hoursMedianFull RangeParticipantsMeasure","NCT03176459","O2","Superiority","0.7536",NA,"Regression, Cox","IR Bupivacaine",NA,NA,NA,NA,NA,NA,NA
"74","Secondary","Opioid-Free Subjects Through 72 Hours","Percentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hours","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Opioid-Free Subjects Through 72 HoursPercentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hoursEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)percent of opioid-free participantsNumberParticipantsMeasure","NCT03176459","O1","Superiority","0.3609",NA,"Regression, Logistic","EXPAREL 266mg + Immediate Release (IR) Bupivacaine","Odds Ratio (OR)","1.14",NA,"2-Sided",NA,NA,NA
"75","Secondary","Opioid-Free Subjects Through 72 Hours","Percentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hours","0-72 hours","Efficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)","Opioid-Free Subjects Through 72 HoursPercentage of subjects who did not received an opioid rescue medication starting from the end of surgery through 72 hoursEfficacy analysis set (also the modified intent-to-treat [mITT] analysis set) included all randomized subjects in the safety analysis set who underwent C-section and who also met the study criteria for correct TAP placement, local anesthetic dosing, and a multimodal post-operative analgesic regimen, with analysis based on randomized treatment (regardless of treatment received)percent of opioid-free participantsNumberParticipantsMeasure","NCT03176459","O2","Superiority","0.3609",NA,"Regression, Logistic","IR Bupivacaine","Odds Ratio (OR)","1.14",NA,"2-Sided",NA,NA,NA
"76","Primary","PCA (Patient Controlled Analgesia) Usage","Will measure the amount of PCA use for the first 48 hours after surgery.","48 hours post operatively","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","PCA (Patient Controlled Analgesia) UsageWill measure the amount of PCA use for the first 48 hours after surgery.The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"77","Secondary","Oral Pain Medications","the amount of post operative oral narcotic is measured post op","48 hours postoperatively","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Oral Pain Medicationsthe amount of post operative oral narcotic is measured post opThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"78","Secondary","Total IV (Intravenous) Narcotic Used","the total amount of IV narcotic is measured that is given during post op period prior to discharge","participants will be followed for the duration of hospital stay, an expected average of 3 days","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Total IV (Intravenous) Narcotic Usedthe total amount of IV narcotic is measured that is given during post op period prior to dischargeThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"79","Secondary","Total Oral Narcotic Used",NA,"participants will be followed for the duration of hospital stay, an expected average of 3 days","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Total Oral Narcotic UsedThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"80","Secondary","Length of Stay",NA,"participants will be followed for the duration of hospital stay, an expected average of 3 days",NA,"Length of StaydaysNumberParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"81","Secondary","Return of Bowel Function",NA,"participants will be followed for the duration of hospital stay, an expected average of 3 days, and the timing of return of bowel function returning will be recorded","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Return of Bowel FunctionThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"82","Secondary","Readmission",NA,"30 days post operative readmission","No one readmitted.","ReadmissionNo one readmitted.ParticipantsCount of ParticipantsParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"83","Secondary","Toradol Use",NA,"participants will be followed for the duration of hospital stay, an expected average of 3 days",NA,"Toradol UseParticipantsCount of ParticipantsParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"84","Secondary","Ofirmev",NA,"participants will be followed for the duration of hospital stay, an expected average of 3 days, and the amount of ofirmev used during admission will be recorded","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","OfirmevThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"85","Secondary","Nausea Medication",NA,"The amount of nausea medicine used 48 hours post op was recorded","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Nausea MedicationThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"86","Secondary","Foley Catheter Removal",NA,"participants will be followed for the duration of hospital stay, an expected average of 3 days, the timing of foley catheter removal will be recorded","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Foley Catheter RemovalThe study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"87","Secondary","Postoperative Pain","The investigators will talk to the patient after surgery immediately post operatively Post Operative Day (POD) #3-5 and POD #13-15 and ask the patients to rate their pain on a scale of 1-10.","POD #3-5 and POD #13-15","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Postoperative PainThe investigators will talk to the patient after surgery immediately post operatively Post Operative Day (POD) #3-5 and POD #13-15 and ask the patients to rate their pain on a scale of 1-10.The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"88","Secondary","Post Operative Satisfaction","The investigators will ask the patient to rate their satisfaction with pain control.","POD #3-5 and POD #13-15","The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.","Post Operative SatisfactionThe investigators will ask the patient to rate their satisfaction with pain control.The study personnel have left the institution or are unreachable. efforts were made to contact the PI/study team members but were unsuccessful. Efforts were also made to get data from Mercy IRB and patient records staff. These staff did not have the information to find such data. Available data from the publication has been entered, but no other data is available and all efforts to locate the data have been exhausted.ParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"89","Secondary","Home Oral Narcotic Use","The investigators will ask the patients how many of their narcotic pain pills they used after surgery up to the POD #13-15","POD #13-15",NA,"Home Oral Narcotic UseThe investigators will ask the patients how many of their narcotic pain pills they used after surgery up to the POD #13-15ParticipantsCount of ParticipantsParticipantsMeasure","NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"90","Other Pre-specified","NG (Nasogastric) Placement","We recorded if an NG was placed immediately post operatively","POD #0 if NG was placed",NA,NA,"NCT02052557",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"91","Primary","Total Morphine Equivalents Consumed","Measured as overall intake of any drugs in the opioid class (Morphine Equivalent Dosing)","up to 72 hours post surgery",NA,"Total Morphine Equivalents ConsumedMeasured as overall intake of any drugs in the opioid class (Morphine Equivalent Dosing)MEqMedianInter-Quartile RangeParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"92","Secondary","VAS Pain Score","Using a 10 point visual analog scale (VAS) score. The score ranges from 0 to 10. '0' represents no pain and '10' represents worst pain.","In-hospital until discharge, approximately 3 days, will be collected each time before dispensing pain medications",NA,"VAS Pain ScoreUsing a 10 point visual analog scale (VAS) score. The score ranges from 0 to 10. '0' represents no pain and '10' represents worst pain.score on a scaleMedianInter-Quartile RangeParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"93","Secondary","Treatment Cost","All direct cost from the date of surgery until discharge","In-hospital Costs until discharge, approximately 3 days",NA,"Treatment CostAll direct cost from the date of surgery until dischargeUnited States DollarsMedianInter-Quartile RangeParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"94","Secondary","Pharmacy Cost","Median In-hospital pharmacy cost","In-hospital until discharge, approximately 3 days",NA,"Pharmacy CostMedian In-hospital pharmacy costUnited States DollarsMedianInter-Quartile RangeParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"95","Secondary","Mortality","Any death occurring during primary hospital stay or prior to 30 days post surgery","Up to 30 days post surgery",NA,"MortalityAny death occurring during primary hospital stay or prior to 30 days post surgeryParticipantsCount of ParticipantsParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"96","Other Pre-specified","Hospital Stay",NA,"Length of hospital stay - from admission to discharge, approximately 3 days",NA,"Hospital StayDaysMedianInter-Quartile RangeParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"97","Other Pre-specified","Pneumothorax","Documented pnuemothorax","In-hospital until discharge, approximately 3 days",NA,"PneumothoraxDocumented pnuemothoraxParticipantsCount of ParticipantsParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"98","Other Pre-specified","Prolonged Air Leak","Number of patients who had air leak more than 5 days post-surgery","> 5 days to 7 days",NA,"Prolonged Air LeakNumber of patients who had air leak more than 5 days post-surgeryParticipantsCount of ParticipantsParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"99","Other Pre-specified","Atrial Fibrillation/Other Arrhythmia","Post-op arrhythmia","In-hospital until discharge, approximately 3 days",NA,"Atrial Fibrillation/Other ArrhythmiaPost-op arrhythmiaParticipantsCount of ParticipantsParticipantsMeasure","NCT03682224",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
